Study guide

23.4 Anti-Infectives, Corticosteroids, NSAIDs, Allergy Agents, Lubricants, Supplements & Anti-VEGF

IJCAHPO Certified Ophthalmic Medical Technologist COMT

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The COMT Examination, Eligibility & Certification Requirements

1.1 The 190-Question Multiple-Choice Examination & the 22 Official Content Areas 1.2 The COT Skill Evaluation & the COMT Performance Test 1.3 Eligibility Pathways, Fees, Timelines & Recertification

2 Chapter 2: General Medical Knowledge I — Ocular Anatomy & Physiology

2.1 Orbit, Eyelids, Lacrimal System, Conjunctiva & Extraocular Muscles 2.2 Cornea, Sclera, Anterior Chamber, Angle, Aqueous Dynamics & Crystalline Lens 2.3 Uvea, Retina, Vitreous, Optic Nerve, Ocular Circulation & the Visual Pathway

3 Chapter 3: General Medical Knowledge II — Eye Disease, Systemic Manifestations, Terminology & Safety

3.1 Frequently Encountered Eye Conditions by Structure & Inflammation Versus Infection 3.2 Body Systems & the Ocular Manifestations of Systemic Disease 3.3 Medical Terminology, Approved Abbreviations, Hazardous Waste & Clinic Safety

4 Chapter 4: Ophthalmic History Taking & Clinical Documentation

4.1 The Five History Domains: Ocular, Medical, Medication, Social & Family 4.2 Charting Conventions, Scribing & the Electronic Medical Record

5 Chapter 5: Visual Assessment, Accommodative Testing & Low Vision

5.1 Measuring Acuity at Every Level & in Preliterate, Illiterate and Non-Verbal Patients 5.2 Stereoacuity, Near Point of Accommodation, Near Point of Convergence & the AC/A Ratio 5.3 Low Vision Assessment, Magnification Calculation & Device Instruction

6 Chapter 6: Tonometry, Keratometry & Pupil Measurement

6.1 Goldmann Applanation Tonometry: Technique, Sources of Error & the Imbert-Fick Principle 6.2 Hand-Held Applanators, Non-Contact Tonometry, Rebound Tonometry & Disinfection 6.3 Manual & Automated Keratometry: Technique, Readings and Interpretation 6.4 Pupil Measurement, Shape, Reactivity & Evaluating Anisocoria

7 Chapter 7: Lensometry, Spectacle Optics & Prescription Analysis

7.1 Manual Lensometry: Eyepiece Focus, Neutralising Sphere, Cylinder & Axis 7.2 Neutralising Reading Adds: Bifocal, Trifocal, Progressive & Determining the Near Add 7.3 Identifying & Measuring Prism: Ground-In, Decentration, Fresnel Press-On & Slab-Off 7.4 Transposition, Spherical Equivalent, Vertex Distance & Prescription Components 7.5 The Geneva Lens Clock, Lens Materials, Progressive Markings & Spectacle Adjustment

8 Chapter 8: Refraction, Retinoscopy & Refinement

8.1 Autorefraction, Refractive Error Types & Establishing an Objective Starting Point 8.2 Streak Retinoscopy: With Motion, Against Motion, Neutralisation & Working Distance 8.3 Subjective Refinement: Fogging, Jackson Cross Cylinder, Duochrome & Binocular Balance 8.4 Near Add Determination, Vertex Recording & Refraction in Difficult Situations

9 Chapter 9: Ocular Motility, Strabismus & Advanced Optics

9.1 Ocular Kinematics: Ductions, Versions, Vergences, Hering's & Sherrington's Laws 9.2 Quantitative Strabismus Measurements: Alternate Cover Test, Prism Cover Test & Lancaster Red-Green / Hess Screen 9.3 Cranial Nerve Palsies (CN III, IV, VI), Restrictive Myopathies & Forced Duction Testing 9.4 Clinical Optics, Prentice's Rule, Slab-Off Prisms & Wavefront Aberrations

10 Chapter 10: Sensory Fusion Testing, Nystagmus, Amblyopia & Vergence Therapy

10.1 Sensory Fusion Testing: Worth 4-Dot, Maddox Rod & Bagolini Lenses 10.2 Hirschberg, Krimsky, Brückner & Fusional Vergence Amplitudes 10.3 Nystagmus, Amblyopia Therapy & Convergence Training

11 Chapter 11: Advanced Visual Fields & Neuro-Ophthalmic Evaluation

11.1 Amsler Grid & Confrontation Visual Field Testing 11.2 Automated Static Perimetry: HFA Strategies (SITA Standard, SITA Fast), Reliability Indices & Statpac Analysis 11.3 Visual Field Defect Patterns: Glaucomatous Nerve Fiber Bundle Deficits vs. Retinal Pathology 11.4 Kinetic Perimetry (Goldmann Perimetry) & Neurological Visual Pathway Defect Localization 11.5 Pupillary Pathways, RAPD Quantitation with Neutral Density Filters & Pharmacologic Testing

12 Chapter 12: Supplemental Testing — Glare, PAM, Colour Vision, Tear Film & Slit Lamp Technique

12.1 Glare Testing, Potential Acuity Meter & Contrast Sensitivity 12.2 Colour Vision: Pseudoisochromatic Plates, Farnsworth-Munsell D-15 & the 100-Hue Test 12.3 Tear Film Assessment: Schirmer, Tear Break-Up Time, Vital Dyes & Corneal Sensitivity 12.4 Slit Lamp Technique, Slit Lamp Lenses, Direct Ophthalmoscopy & Pen Light Examination 12.5 Exophthalmometry, Head & Posture Assessment and Wavefront Diagnostics

13 Chapter 13: Full-Field Electroretinography & ISCEV Protocols

13.1 Retinal Neurophysiology & Electrophysiologic Origin of Waveforms 13.2 ISCEV Standard Full-Field ERG Protocol & Electrode Systems 13.3 Dark-Adapted (Scotopic) Testing: Rod-Driven Responses & Combined Maximal Response 13.4 Light-Adapted (Photopic) Testing: Cone Response, 30-Hz Flicker & Oscillatory Potentials

14 Chapter 14: Advanced Electrophysiologic Testing (mfERG, PERG, VEP, EOG)

14.1 Multifocal Electroretinogram (mfERG): Topographic Retinal Mapping 14.2 Pattern Electroretinogram (PERG): Ganglion Cell & Macular Function 14.3 Visual Evoked Potentials (VEP): Flash, Pattern & Visual Pathway Integrity 14.4 Electrooculogram (EOG), Arden Ratio & RPE Light Peak Dynamics

15 Chapter 15: Fluorescein Angiography Principles & Technique

15.1 Fluorescein Angiography Principles, Exciter/Barrier Filters & Injection Protocol 15.2 Normal Transit Phases & Retinal/Choroidal Circulation Hemodynamics 15.3 Adverse Reactions, Patient Safety & Emergency Management

16 Chapter 16: Angiographic Interpretation & Pathology

16.1 Hyperfluorescence Mechanisms: Leakage, Staining, Pooling, Window Defects & Autofluorescence 16.2 Hypofluorescence Mechanisms: Vascular Non-Perfusion & Blocking Defects 16.3 Indocyanine Green (ICG) Angiography: Principles, Indications & Choroidal Pathology

17 Chapter 17: Advanced Fundus Imaging & Optical Coherence Tomography

17.1 Fundus Autofluorescence (FAF) & Ultra-Widefield Fundus Imaging 17.2 Spectral-Domain and Swept-Source OCT: Retinal Layer Architecture & Quantitative Analysis 17.3 Enhanced Depth Imaging (EDI-OCT) & Anterior Segment OCT (AS-OCT) 17.4 Optical Coherence Tomography Angiography (OCTA): Chorioretinal Plexuses & Biomarkers

18 Chapter 18: Ophthalmic Photography & Videography

18.1 The Fundus Camera: Optics, Alignment & Correcting Artefacts 18.2 Standard Fundus Photography: ETDRS Fields, Stereo Pairs, Red-Free & Wide-Field Imaging 18.3 Slit Lamp & Anterior Segment Photography 18.4 External Photography, Nine-Gaze Motility Documentation & Image Management

19 Chapter 19: Ophthalmic Echography (A-Scan, B-Scan & UBM)

19.1 Physics of Ophthalmic Ultrasound, Acoustic Impedance & Probe Transducers 19.2 Standardized Diagnostic A-Scan: Acoustic Spikes, Tissue Reflectivity & Attenuation 19.3 Diagnostic B-Scan Echography: Topographic, Kinetic & Quantitative Vitreoretinal Evaluation 19.4 Ultrasound Biomicroscopy (UBM): Anterior Segment Anatomy, Angle Pathology & Ciliary Body Imaging

20 Chapter 20: Biometry, Topography & Corneal Analysis

20.1 Optical Biometry vs. Immersion/Contact Ultrasound Biometry 20.2 Intraocular Lens (IOL) Power Calculation Formulas & Post-Refractive Adjustments 20.3 Corneal Topography, Scheimpflug Tomography & Keratoconus Screening 20.4 Corneal Pachymetry, Endothelial Specular Microscopy & Anterior Chamber Depth

21 Chapter 21: Rigid Gas Permeable & Specialty Lens Fitting

21.1 Rigid Gas Permeable (RGP) Material Properties, Dk/t & Oxygen Permeability 21.2 RGP Base Curve Selection, Diagnostic Fitting & Fluorescein Pattern Evaluation 21.3 Scleral Contact Lens Design, Sagittal Depth Fitting & Clearance Evaluation 21.4 Keratoconus, Irregular Corneas & Hybrid Contact Lens Systems

22 Chapter 22: Toric, Multifocal, Therapeutic Lenses & Complications

22.1 Toric Soft Contact Lens Dynamics, Stabilization Techniques & LARS Rule 22.2 Presbyopic & Multifocal Contact Lens Systems: Simultaneous vs. Translating Designs 22.3 Therapeutic Bandage Contact Lenses, Amniotic Membranes & Orthokeratology 22.4 Contact Lens-Induced Pathology, Giant Papillary Conjunctivitis & Infectious Keratitis

23 Chapter 23: Ocular Pharmacology

23.1 Routes of Drug Delivery, Prescription Components & Instillation Technique 23.2 Mydriatics, Cycloplegics, Anaesthetics & Diagnostic Agents 23.3 Glaucoma Medications: Classes, Mechanisms & Side Effects 23.4 Anti-Infectives, Corticosteroids, NSAIDs, Allergy Agents, Lubricants, Supplements & Anti-VEGF

24 Chapter 24: Microbiology & Ocular Specimen Collection

24.1 Types of Microorganisms & Pathways of Disease Transmission 24.2 Assisting with Conjunctival & Corneal Specimen Collection

25 Chapter 25: Anterior Segment, Glaucoma & Refractive Surgery

25.1 Advanced Phacoemulsification, Surgical Steps, Fluidics & Complication Management 25.2 Premium Intraocular Lenses: Toric, Multifocal, EDOF & Lens Exchange 25.3 Glaucoma Surgical Procedures: Trabeculectomy, Aqueous Shunts & MIGS Devices 25.4 Laser In Situ Keratomileusis (LASIK), PRK, SMILE & Phakic IOLs

26 Chapter 26: Vitreoretinal, Corneal & Trauma Surgery

26.1 Pars Plana Vitrectomy (PPV), Scleral Buckling & Intraocular Tamponades (Gas/Silicone Oil) 26.2 Corneal Transplantation: Penetrating Keratoplasty (PKP) & Lamellar Keratoplasty (DSAEK, DMEK, DALK) 26.3 Ocular Trauma Repair: Open Globe Management, Hyphema, Vitreous Loss & Endophthalmitis Protocol

27 Chapter 27: Surgical Asepsis, Instrumentation & Laser Procedures

27.1 Operating Room Sterilization, Aseptic Field Maintenance & Universal Precautions 27.2 Microsurgical Instrumentation, Maintenance & Sharps Safety 27.3 Ophthalmic Laser Physics, Delivery Systems & Safety (Nd:YAG, Argon/FD-Nd:YAG, SLT)

28 Chapter 28: Ophthalmic Patient Services & Education

28.1 Communicating with Patients, Families and Colleagues, and Handling Dissatisfaction 28.2 Patient Education & Counselling on Conditions, Medications, Tests and Results 28.3 Ophthalmic Emergencies, First Aid, Vital Signs & CPR 28.4 Triage, Urgency-Based Scheduling, Patient Flow & Telephone Management 28.5 Dressings and Shields, Prosthetics, Legal Forms, Referrals & Reimbursement Support

29 Chapter 29: Clinic Operations — Equipment Maintenance, Ethics, Coding & Compliance

29.1 Equipment Maintenance, Calibration, Emergency Equipment & Inventory 29.2 Confidentiality, Informed Consent, Scope of Practice & Ethical Standards 29.3 Coding, Scribing Compliance, Quality Assurance & Regulatory Requirements

23.4 Anti-Infectives, Corticosteroids, NSAIDs, Allergy Agents, Lubricants, Supplements & Anti-VEGF

Key Takeaways Explain This Topic AI

Topical corticosteroids raise intraocular pressure in steroid responders and accelerate posterior subcapsular cataract.

Steroid monotherapy is contraindicated in herpes simplex epithelial keratitis and in untreated fungal keratitis.

Fluoroquinolones are the usual empirical choice for bacterial keratitis; fortified antibiotics are used for severe ulcers.

Preservative-free artificial tears are preferred when drops are used more than four to six times daily.

AREDS2 supplementation is indicated for intermediate or advanced age-related macular degeneration, not for prevention in healthy eyes.

Last updated: September 2026

Anti-infective agents

Anti-bacterial.

Group Examples Typical use

Fluoroquinolones Moxifloxacin, gatifloxacin, ciprofloxacin, ofloxacin, levofloxacin Broad spectrum; first-line empirical treatment for bacterial keratitis and post-operative prophylaxis

  • Aminoglycosides Tobramycin, gentamicin Gram-negative cover; epithelial toxicity with prolonged use
  • Macrolides Erythromycin ointment, azithromycin drops Gram-positive; blepharitis; neonatal prophylaxis
  • Polymyxin combinations Polymyxin B with trimethoprim or bacitracin Broad-spectrum conjunctivitis cover

Fortified antibiotics Fortified cefazolin or vancomycin plus fortified tobramycin or an aminoglycoside Severe or sight-threatening ulcers; compounded, refrigerated, short shelf life, often hourly dosing including overnight

Patient instruction for a corneal ulcer regimen is a technologist task with real consequences: hourly drops including through the night , a five-minute gap between different agents, no contact lens wear, and daily review. A patient who does not understand the overnight dosing will under-treat a sight-threatening infection.

Anti-viral. Ganciclovir 0.15% gel and trifluridine 1% drops for herpes simplex epithelial keratitis; oral aciclovir, valaciclovir and famciclovir for herpes zoster ophthalmicus and for prophylaxis in recurrent herpes simplex. The key teaching point: corticosteroid monotherapy in herpes simplex epithelial keratitis is contraindicated — it promotes viral replication and can turn a dendrite into a geographic ulcer.

Anti-fungal. Natamycin 5% suspension is first-line for filamentous fungal keratitis; voriconazole and amphotericin are used topically, and oral or intravenous agents for deep or severe disease. Fungal keratitis is slow to treat, often taking many weeks, and steroids are avoided .

Anti-parasitic. Acanthamoeba keratitis is treated with biguanides (polyhexamethylene biguanide, chlorhexidine) with or without a diamidine, often for months. Prevention is the practical message: contact lenses must never be rinsed or stored in tap water, and should not be worn while swimming or showering.

Corticosteroids

  • Agent Relative potency Typical use
  • Prednisolone acetate 1% High Post-operative, uveitis; a suspension — shake well
  • Dexamethasone 0.1% High Post-operative, inflammation
  • Difluprednate 0.05% Very high Severe inflammation; higher pressure-rise risk
  • Loteprednol 0.2–0.5% Moderate, ester steroid Lower pressure-rise risk; chronic surface inflammation
  • Fluorometholone 0.1% Lower penetration Surface inflammation, allergy

The three complications to know:

Steroid-induced ocular hypertension. About a third of the population are steroid responders and a small percentage are high responders. Pressure must be checked at intervals in anyone on a topical steroid beyond a couple of weeks.

Posterior subcapsular cataract — dose and duration related, and irreversible.

Potentiation of infection — herpes simplex, fungal and bacterial keratitis all worsen, and epithelial healing is delayed.

Taper rather than stop abruptly after prolonged use, to avoid rebound inflammation.

Non-steroidal anti-inflammatory drugs

Examples: ketorolac, diclofenac, nepafenac, bromfenac, flurbiprofen.

Mechanism: inhibit cyclo-oxygenase and therefore prostaglandin synthesis.

Uses: post-operative inflammation and pain, prevention and treatment of cystoid macular oedema , maintaining intraoperative mydriasis (flurbiprofen), allergic conjunctivitis itch, and post-refractive-surgery discomfort.

Advantage over steroids: they do not raise intraocular pressure and do not cause cataract.

Risks: stinging, and — importantly — corneal melting with prolonged use, particularly in dry eye, diabetes, rheumatoid arthritis, neurotrophic corneas and after surgery. Any patient on a topical NSAID with a persistent epithelial defect must be reviewed.

Allergy medications

Class Examples Onset / role

Antihistamine / mast cell stabiliser combinations Olopatadine, ketotifen, azelastine, bepotastine, alcaftadine Rapid itch relief and prophylaxis; the usual first choice

Mast cell stabilisers Cromolyn, lodoxamide, nedocromil Prophylactic; need days to weeks to work, so they must be started before the season

  • Topical antihistamines Emedastine Rapid, short-acting
  • Topical NSAIDs Ketorolac Itch relief
  • Topical steroids Loteprednol, fluorometholone Severe or vernal disease, short courses under supervision
  • Decongestants Naphazoline, tetrahydrozoline Whitening only; rebound hyperaemia with regular use — discourage

Non-pharmacological measures matter and should be taught: cool compresses, allergen avoidance, preservative-free lubricants to dilute allergen, refrigerating the drops, and not rubbing the eyes — rubbing degranulates mast cells and is also associated with keratoconus progression.

Ocular lubricants

  • Form Notes
  • Preserved drops Acceptable up to about four times daily

Preservative-free drops Required when used more than four to six times daily , and in surface disease, because benzalkonium chloride is directly toxic to the epithelium with frequent use

  • Gels Longer contact, transient blur; often evening use
  • Ointments Longest contact, marked blur; usually bedtime only
  • Lipid-containing emulsions Target evaporative dry eye and meibomian dysfunction

Also relevant: cyclosporine 0.05% and lifitegrast 5% for aqueous-deficient and inflammatory dry eye — both take weeks to months to show benefit, and patients must be told so or they will abandon treatment.

Nutritional supplements

AREDS2 formulation: vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg (or a lower zinc dose), copper 2 mg, lutein 10 mg and zeaxanthin 2 mg.

Indication: intermediate or advanced age-related macular degeneration — it slows progression in those eyes. It is not indicated for prevention in healthy eyes or in early macular degeneration.

The beta-carotene point: the original AREDS formula contained beta-carotene, which increased lung cancer risk in smokers and former smokers . AREDS2 replaced it with lutein and zeaxanthin. Never recommend a beta-carotene-containing formula to a smoker.

Omega-3 supplementation is widely used for dry eye, with mixed trial evidence.

Anti-neovascular (anti-VEGF) agents

Examples: ranibizumab, aflibercept, bevacizumab (used off-label), brolucizumab, faricimab.

Mechanism: bind vascular endothelial growth factor, reducing neovascularisation and vascular leakage.

Indications: neovascular age-related macular degeneration, diabetic macular oedema, proliferative diabetic retinopathy, macular oedema from retinal vein occlusion, myopic choroidal neovascularisation and retinopathy of prematurity.

Administration: intravitreal injection under strict aseptic technique, initially monthly then on a treat-and-extend or as-needed schedule.

Risks to counsel: endophthalmitis (rare but devastating), retinal detachment, intraocular inflammation, transient pressure rise, subconjunctival haemorrhage (common, alarming, benign) and a theoretical systemic thromboembolic risk.

Post-injection instruction the technologist usually delivers: expect floaters and a red patch on the white of the eye; do not rub the eye; and return immediately for increasing pain, worsening vision, increasing redness or discharge, because those are the warning signs of endophthalmitis. Give the instruction in writing as well as verbally.